Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10995739 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Zheng WH, Kar S, Quirion R (2000) Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells. J Biol Chem 275, 39152-8 10995739
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T32-p - FOXO3A (human) ▲
Orthologous residues
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (rat) pharmacological activator of upstream enzyme, phospho-motif antibody, transfection of dominant-negative enzyme, transfection of constitutively active enzyme, phospho-antibody, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme

S253-p - FOXO3A (human) ▲
Orthologous residues
FOXO3A (human): S253‑p, FOXO3A (mouse): S252‑p, FOXO3A (rat): S252‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (rat) pharmacological activator of upstream enzyme, phospho-motif antibody, transfection of dominant-negative enzyme, transfection of constitutively active enzyme, phospho-antibody, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme

T32-p - FOXO3A (rat) ▲
Orthologous residues
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (rat) pharmacological activator of upstream enzyme, phospho-motif antibody, transfection of dominant-negative enzyme, transfection of constitutively active enzyme, phospho-antibody, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase
LY294002 IGF-1 inhibit treatment-induced increase
PD98059 IGF-1 no effect upon treatment-induced increase
rapamycin IGF-1 no effect upon treatment-induced increase

S252-p - FOXO3A (rat) ▲
Orthologous residues
FOXO3A (human): S253‑p, FOXO3A (mouse): S252‑p, FOXO3A (rat): S252‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  human, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (rat) pharmacological activator of upstream enzyme, phospho-motif antibody, transfection of dominant-negative enzyme, transfection of constitutively active enzyme, phospho-antibody, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
wortmannin IGF-1 inhibit treatment-induced increase
LY294002 IGF-1 inhibit treatment-induced increase
PD98059 IGF-1 no effect upon treatment-induced increase
rapamycin IGF-1 no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.